ResMed, Inspire Medical Drop After Lilly’s Zepbound Study by Mark Eisenberg 24.06.2024 "ResMed and Inspire Medical stocks plummet after Eli Lilly's Zepbound trial success; Citi downgrades RMD, sees market shift. Read more ...
Covaxin Patent Issue: Bharat Biotech to Credit ICMR by Lilu Anderson 23.06.2024 Bharat Biotech admits patent oversight on Covaxin, pledges to include ICMR scientists in new filings to uphold transparency and legal ...
U.S. Crackdown on Chinese Biotech Could Harm Patients by Lilu Anderson 22.06.2024 America's crackdown on Chinese biotech could lead to drug shortages and higher costs, impacting patients without delivering promised security benefits.
ADC Therapeutics Director Azelby Sells Shares Amid Price Target Cut by Mark Eisenberg 20.06.2024 Robert Azelby sells $20,215 in ADC Therapeutics shares for tax reasons; holds 53,005 shares. Investors eye insider actions for future ...
Biotech’s Big Gamble Fails: Insights and Implications by Lilu Anderson 18.06.2024 Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
Biotech’s Big Gamble Fails: Insights and Implications by Lilu Anderson 18.06.2024 Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
Aerovate Therapeutics Stock Downgraded After Trial Setback by Mark Eisenberg 17.06.2024 Aerovate Therapeutics stock downgraded by BTIG after AV-101 trial setback; mixed analyst views and future pivotal readouts crucial for investors.
Nexalin Tech’s Short Interest Drops 16.9% Amid Volatility by Terry Bingman 16.06.2024 Nexalin shares are 1% shorted; 52-week range $0.25-$3.40. Market cap: $6.69M, PE ratio: -1.36, beta: 5.13. Qtr EPS: -$0.10; ROE: ...
Tempus AI Raises $410M in IPO, Sees Revenue Surge by Mark Eisenberg 15.06.2024 Tempus AI sold 11M shares at $37 each, launched in 2015, focuses on medical testing, with revenue growth from $320.7M ...
Altimmune’s Promising GLP-1 Drug: Worth the Investment? by Mark Eisenberg 25.04.2024 Altimmune's stock has seen a strong increase in value, surpassing Eli Lilly and Novo Nordisk. However, there are risks involved.